Effectiveness of an individualized home-based physical activity program in surgery-free non-endarterectomized asymptomatic stroke patients: a study protocol for the PACAPh interventional randomized trial.
Atherosclerosis
Intraplaque hemorrhage
Monocyte phenotype
Physical activity
Physical fitness
Randomized controlled trial
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
14 Feb 2022
14 Feb 2022
Historique:
received:
13
10
2021
accepted:
27
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
17
2
2022
Statut:
epublish
Résumé
Carotid atherosclerotic plaques remain silent until their rupture, which may lead to detrimental ischemic events such as strokes. This is due, in part, to intraplaque hemorrhages (IPH) and the resulting inflammatory processes, which may promote carotid plaque vulnerability. Currently, the benefits of carotid endarterectomy remain unclear for asymptomatic patients. Interestingly, the completion of physical activity (PA) may have beneficial effects; however, the paucity of current data warrants robust longitudinal interventions. We therefore aim to study the effects of a 6-month longitudinal personalized home-based PA program on IPH, biological, and inflammatory markers in asymptomatic stroke patients. Eighty patients (≥ 18 years old) will be recruited for the Physical Activity and Carotid Atherosclerotic Plaque Hemorrhage (PACAPh) clinical trial from the Hospices Civils de Lyon. Patients will be eligible if they present with carotid stenosis ≥ 50% and are asymptomatic from any ischemic events for at least 6 months. Recruited patients will be randomized into either a PA or a control group, and assessed at baseline and after 6 months. At both time points, all patients will be assessed using magnetic resonance imaging to assess IPH, blood sampling to measure inflammatory markers and monocytic phenotyping, PA and sedentary behavior questionnaires, 6-min walking test, and maximal isometric quadricep contraction test. The randomized PA intervention will consist of reaching a daily walking step goal individually tailored to each patient. Steps will be collected using a wirelessly connected wristband. The number of steps completed by individuals in the PA group will be re-evaluated bimonthly to encourage walking habits. The PACAPh study is the first of its kind representing a feasible, easily accessible therapeutic strategy for asymptomatic stroke patients. We hypothesize that the personalized home-based PA program will reduce IPH and modulate inflammatory and biological parameters in patients presenting with carotid plaques. If the results of the PACAPh study prove to be beneficial on such health parameters, the implementation of such kind of intervention in the daily treatment of these patients would be an advantageous and cost-effective practice to adopt globally. This study has been approved by the National Ethics Committee (IDRCB:2019-A01543-54/SI:19.06.21.40640). ClinicalTrials.gov NCT04053166.
Sections du résumé
BACKGROUND
BACKGROUND
Carotid atherosclerotic plaques remain silent until their rupture, which may lead to detrimental ischemic events such as strokes. This is due, in part, to intraplaque hemorrhages (IPH) and the resulting inflammatory processes, which may promote carotid plaque vulnerability. Currently, the benefits of carotid endarterectomy remain unclear for asymptomatic patients. Interestingly, the completion of physical activity (PA) may have beneficial effects; however, the paucity of current data warrants robust longitudinal interventions. We therefore aim to study the effects of a 6-month longitudinal personalized home-based PA program on IPH, biological, and inflammatory markers in asymptomatic stroke patients.
METHODS
METHODS
Eighty patients (≥ 18 years old) will be recruited for the Physical Activity and Carotid Atherosclerotic Plaque Hemorrhage (PACAPh) clinical trial from the Hospices Civils de Lyon. Patients will be eligible if they present with carotid stenosis ≥ 50% and are asymptomatic from any ischemic events for at least 6 months. Recruited patients will be randomized into either a PA or a control group, and assessed at baseline and after 6 months. At both time points, all patients will be assessed using magnetic resonance imaging to assess IPH, blood sampling to measure inflammatory markers and monocytic phenotyping, PA and sedentary behavior questionnaires, 6-min walking test, and maximal isometric quadricep contraction test. The randomized PA intervention will consist of reaching a daily walking step goal individually tailored to each patient. Steps will be collected using a wirelessly connected wristband. The number of steps completed by individuals in the PA group will be re-evaluated bimonthly to encourage walking habits.
DISCUSSION
CONCLUSIONS
The PACAPh study is the first of its kind representing a feasible, easily accessible therapeutic strategy for asymptomatic stroke patients. We hypothesize that the personalized home-based PA program will reduce IPH and modulate inflammatory and biological parameters in patients presenting with carotid plaques. If the results of the PACAPh study prove to be beneficial on such health parameters, the implementation of such kind of intervention in the daily treatment of these patients would be an advantageous and cost-effective practice to adopt globally.
TRIAL REGISTRATION
BACKGROUND
This study has been approved by the National Ethics Committee (IDRCB:2019-A01543-54/SI:19.06.21.40640). ClinicalTrials.gov NCT04053166.
Identifiants
pubmed: 35164816
doi: 10.1186/s13063-022-06061-x
pii: 10.1186/s13063-022-06061-x
pmc: PMC8842739
doi:
Banques de données
ClinicalTrials.gov
['NCT04053166']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
145Subventions
Organisme : Société Francaise de cardiologie
ID : NA
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2054-61
pubmed: 16037567
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Clin Hemorheol Microcirc. 2009;42(2):75-97
pubmed: 19433882
Sports Med. 2018 Dec;48(12):2725-2741
pubmed: 30302720
Nature. 2002 Dec 19-26;420(6917):868-74
pubmed: 12490960
Nature. 2011 May 19;473(7347):317-25
pubmed: 21593864
Acta Physiol (Oxf). 2015 Mar;213(3):539-53
pubmed: 25515699
Eur J Vasc Endovasc Surg. 2018 Mar;55(3):305-368
pubmed: 28851596
Blood. 2019 Jun 6;133(23):2529-2541
pubmed: 30952675
J Appl Physiol (1985). 2011 Jul;111(1):308-10
pubmed: 21617083
JAMA. 1993 May 12;269(18):2386-91
pubmed: 8479064
Rural Remote Health. 2011;11(2):1532
pubmed: 21488706
Am J Hematol. 2014 Feb;89(2):228-32
pubmed: 24123050
Blood. 2015 Oct 15;126(16):1940-8
pubmed: 26324704
Support Care Cancer. 2018 Oct;26(10):3323-3336
pubmed: 29909476
Atherosclerosis. 2010 Oct;212(2):668-73
pubmed: 20723894
Eur J Prev Cardiol. 2012 Jun;19(3):494-503
pubmed: 22779092
Lancet Glob Health. 2020 May;8(5):e721-e729
pubmed: 32353319
Br J Sports Med. 2020 Apr;54(8):469-474
pubmed: 30842104
PLoS One. 2015 Apr 27;10(4):e0124448
pubmed: 25915545
Adv Exp Med Biol. 2010;682:279-96
pubmed: 20824532
Proc Nutr Soc. 1973 May;32(1):45A
pubmed: 4760798
Ann Transl Med. 2020 Oct;8(19):1273
pubmed: 33178805
Chin Med J (Engl). 2017 Oct 5;130(19):2375-2379
pubmed: 28937045
Eur J Health Econ. 2013 Jul;14 Suppl 1:S1-3
pubmed: 23900659
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Atherosclerosis. 2014 Jun;234(2):311-9
pubmed: 24726899
Radiology. 2001 Nov;221(2):285-99
pubmed: 11687667
Eur J Appl Physiol Occup Physiol. 1987;56(6):679-85
pubmed: 3678222
N Engl J Med. 1999 Jan 14;340(2):115-26
pubmed: 9887164
N Engl J Med. 1991 Aug 15;325(7):445-53
pubmed: 1852179
JMIR Res Protoc. 2018 Aug 30;7(8):e10487
pubmed: 30166274
Microcirculation. 2013 Apr;20(3):203-16
pubmed: 23121167
Eur J Clin Nutr. 2015 Sep;69(9):977-1003
pubmed: 25711954
J Am Coll Cardiol. 2009 Apr 28;53(17):1517-27
pubmed: 19389562
Med J Aust. 2007 Jan 1;186(1):21-5
pubmed: 17229029
J Sports Sci. 2002 Apr;20(4):345-52
pubmed: 12003280
Heart. 2011 Jul;97(14):1169-74
pubmed: 21561899
Ann Vasc Surg. 1997 Jul;11(4):374-7
pubmed: 9236993
Circulation. 2012 Dec 11;126(24):2890-909
pubmed: 23159553
PLoS One. 2011 Feb 09;6(2):e14669
pubmed: 21347403
Heart. 2016 Aug 1;102(15):1183-92
pubmed: 26936337
J Phys Act Health. 2009 Nov;6(6):790-804
pubmed: 20101923
Contemp Clin Trials. 2018 Jan;64:13-21
pubmed: 29129704
JMIR Mhealth Uhealth. 2018 Mar 01;6(3):e47
pubmed: 29496655
Neurology. 2005 Jul 12;65(1):107-12
pubmed: 16009894
Aging Clin Exp Res. 2019 Feb;31(2):163-173
pubmed: 29714027
Fam Pract. 2007 Sep;24(4):343-57
pubmed: 17630271
J Appl Physiol (1985). 2011 Aug;111(2):599-605
pubmed: 21596926
J Physiol. 1969 Oct;204(2):63P-66P
pubmed: 5824654
Presse Med. 2013 Jul-Aug;42(7-8):e245-58
pubmed: 23490635
J Vasc Surg. 2008 Mar;47(3):523-9
pubmed: 18234465
Mediators Inflamm. 2008;2008:109502
pubmed: 19148295
J Sports Med Phys Fitness. 1994 Mar;34(1):45-9
pubmed: 7934010
ARYA Atheroscler. 2014 Nov;10(6):319-33
pubmed: 25815022
J Phys Act Health. 2010 Nov;7(6):697-705
pubmed: 21088299
Cochrane Database Syst Rev. 2017 Jun 30;6:CD007130
pubmed: 28665511
Lancet. 1998 May 9;351(9113):1379-87
pubmed: 9593407
Circulation. 2021 Feb 23;143(8):e254-e743
pubmed: 33501848
J Neurosci. 2003 Sep 3;23(22):7974-80
pubmed: 12954858
Cochrane Database Syst Rev. 2010 Aug 04;(8):CD007228
pubmed: 20687083
Nat Rev Cardiol. 2011 Oct 11;9(2):116-24
pubmed: 21989048
J Vasc Surg. 2017 Jun;65(6):1762-1768
pubmed: 28259579